<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00304720</url>
  </required_header>
  <id_info>
    <org_study_id>RMBMT-124-A</org_study_id>
    <nct_id>NCT00304720</nct_id>
  </id_info>
  <brief_title>Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor</brief_title>
  <official_title>Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression After Conditioning With Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA-Matched Family Donor Hematopoietic Cell Transplants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Colorado Blood Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Colorado Blood Cancer Institute</source>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      A. To determine whether stable allogeneic hematopoietic engraftment can be safely established&#xD;
      in patients receiving a non-myeloablative allogeneic SCT from a matched sibling donor, with&#xD;
      fludarabine and low-dose TBI, with pre- and post-transplant immunosuppression with tacrolimus&#xD;
      and MMF.&#xD;
&#xD;
      B. To evaluate the incidence of grade II-IV GVHD associated with this treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Conditioning regimen:&#xD;
&#xD;
        1. Days - 4 to -2: Fludarabine 30 mg/m2/day IV.&#xD;
&#xD;
        2. Day 0: TBI 2.0 Gy at 6-7 cGy/min from a linear accelerator, followed by stem-cell&#xD;
           infusion. TBI will preferably be administered between 7:00 a.m. and 1:00 p.m. to avoid&#xD;
           proximity to tacrolimus/MMF administration.&#xD;
&#xD;
      Immunosuppression:&#xD;
&#xD;
      Day -3: Start tacrolimus at 0.06 mg/kg PO BID. Day 0: Start MMF at 15 mg/kg PO b.i.d. from&#xD;
      day 0 (PM dose only).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2004</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The main endpoints are day 100 mortality and acute GVHD.</measure>
  </primary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Lymphoma</condition>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Acute Lymphocytic Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus and MMF</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients with AML, ALL, CML, CLL, myelodysplastic syndrome (MDS), NHL, Hodgkin's disease&#xD;
        (HD), or myeloma, who are at significantly higher than usual risk for mortality from&#xD;
        conventional myeloablative allogeneic SCT due to age or comorbidities:&#xD;
&#xD;
          -  Age ³ 50 years with AML or ALL in complete remission or with &lt;10% blasts in bone&#xD;
             marrow&#xD;
&#xD;
          -  Age ³ 50 years with MDS or CML.&#xD;
&#xD;
          -  Age &gt; 50 years with lymphomas or myeloma, who have failed chemotherapy and are not&#xD;
             candidates for an autologous transplant, or who have failed a prior autologous SCT.&#xD;
&#xD;
          -  Patients of any age with CLL or low-grade NHL. Patients with CLL and low-grade NHL&#xD;
             need to have failed at least first-line treatment, with an alkylating agent,&#xD;
             fludarabine or 2-chlorodeoxyadenosine (2-CDA), or anti-CD20 monoclonal antibody&#xD;
             rituximab.&#xD;
&#xD;
             2. Patients with hematological malignancy relapsed after prior autologous&#xD;
             transplantation.&#xD;
&#xD;
             3. Patients at high-risk (&gt;60%) of relapsing after autologous transplantation for&#xD;
             hematological malignancies may receive allogeneic transplant as &quot;consolidative&#xD;
             immunotherapy&quot;. Diagnoses include multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's&#xD;
             lymphoma, AML, ALL and MDS. Minimal duration between autologous and allogeneic&#xD;
             transplants is 4 weeks. 4. Patients of any age with hematologic malignancies treatable&#xD;
             by allogeneic SCT, who, because of pre-existing medical conditions, are considered to&#xD;
             be at significantly increased risk for transplant toxicity using high-dose transplant&#xD;
             regimens. 5. Patients with metastatic renal cell carcinoma. Must have include good&#xD;
             performance status (Karnofsky score &gt; 60%), no active brain metastases, life&#xD;
             expectancy &gt; 6 months, absence of bulky liver metastases. Patients will be treated on&#xD;
             other active disease-specific protocols when available. 6. Patients with other&#xD;
             malignant diseases treatable with allogeneic SCT may be eligible for this protocol on&#xD;
             a case by case basis, if approved by the principal investigator and the BMT attending&#xD;
             physicians group. 7. Available HLA-identical sibling donor, or a phenotypically&#xD;
             HLA-matched family member. 8. Age &lt; 70 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with hematological malignancies eligible for a curative autologous SCT:&#xD;
             intermediate- or high-grade NHL with chemo-sensitive first relapse. HD with&#xD;
             chemo-sensitive first relapse.&#xD;
&#xD;
          2. Age &lt;50 years and eligible for a conventional myeloablative allogeneic SCT.&#xD;
&#xD;
          3. Patients with rapidly progressive intermediate or high- grade NHL, unless in minimal&#xD;
             disease state.&#xD;
&#xD;
          4. Patients with active uncontrolled CNS involvement with malignancy.&#xD;
&#xD;
          5. Fertile men or women unwilling to use contraceptive techniques during and for 12&#xD;
             months following treatment.&#xD;
&#xD;
          6. Females who are pregnant.&#xD;
&#xD;
          7. Patients who are HIV positive&#xD;
&#xD;
          8. Organ dysfunction&#xD;
&#xD;
               1. Left ventricle ejection fraction &lt; 35%.&#xD;
&#xD;
               2. DLCO &lt;35% of predicted, or receiving continuous supplementary oxygen.&#xD;
&#xD;
               3. Liver function tests: total bilirubin &gt;2x the upper limit of normal, and/or&#xD;
                  transaminases &gt;4x the upper limit of normal.&#xD;
&#xD;
               4. Karnofsky score &lt;50 for patients &lt; 60 years, or &lt;70 for patients aged 60 - 69&#xD;
                  years (see appendix B).&#xD;
&#xD;
               5. Creatinine clearance &lt; 60 ml/min.&#xD;
&#xD;
               6. Patients with hypertension that is poorly controlled on antihypertensive therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter A McSweeney, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Colorado Blood Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rocky Mountain Blood and Marrow Transplant Program</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter A McSweeney, MD</last_name>
      <phone>303-336-2184</phone>
      <email>Peter.McSweeney@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Juli B Murphy</last_name>
      <phone>303-285-5087</phone>
      <email>Juli.Murphy@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Robert M Rifkin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter A McSweeney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey V Matous, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Scott I Bearman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark W Brunvand, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael B Maris, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2004</verification_date>
  <study_first_submitted>March 17, 2006</study_first_submitted>
  <study_first_submitted_qc>March 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2006</study_first_posted>
  <last_update_submitted>February 6, 2008</last_update_submitted>
  <last_update_submitted_qc>February 6, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2008</last_update_posted>
  <keyword>Lymphoma</keyword>
  <keyword>Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

